Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
NCT Number: NCT03103412
This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with UC. The relative bioavailability of tofacitinib released from TD-3504 compared to co-administered oral heavy-labeled tofacitinib (15N2-tofacitinib) will also be evaluated.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Anaheim, California, 92801, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for Ulcerative Colitis (UC) subjects:
Exclusion criteria
Exclusion criteria
for Healthy Subjects:
TD-3504
15N2-tofacitinib
Placebo
Time frame: Day 1 through Day 8
To assess the safety & tolerability of TD-3504 following single escalating doses of TD-3504 co-administered with a low dose of 15N2 tofacitinib for 8 days in healthy subjects and subjects with UC by assessing the number, severity, and type of treatment related adverse events.
Time frame: Day 1 through Day 8
To assess the safety & tolerability of TD-3504 following single escalating doses of TD-3504 co-administered with a low dose of 15N2 tofacitinib for 8 days in healthy subjects and subjects with UC by assessing treatment related changes safety laboratory values.
Time frame: Day 1 through Day 4
To assess the systemic exposure of TD-3504 following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
Time frame: Day 1
To assess the systemic exposure of TD-3504 following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
Time frame: Day 1 through Day 4
To assess the systemic exposure of tofacitinib following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
Time frame: Day 1
To assess the systemic exposure of tofacitinib following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
Time frame: Day 1 through Day 4
To assess the systemic exposure of following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
Time frame: Day 1
To assess the systemic exposure of following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
Time frame: Day 1 through Day 4
To assess the relative bioavailability of tofacitinib from TD-3504 relative to 15N2-tofacitinib.
Time frame: Day 1
To assess the relative bioavailability of tofacitinib from TD-3504 relative to 15N2-tofacitinib.
Theravance Biopharma
Industry
Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD-3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.